tiprankstipranks
Advertisement
Advertisement
Crinetics’ ACROBAT Advance Update: What Paltusotine’s Long-Term Data Means for CRNX Investors
PremiumCompany AnnouncementsCrinetics’ ACROBAT Advance Update: What Paltusotine’s Long-Term Data Means for CRNX Investors
17d ago
Crinetics downgraded to Neutral from Buy at UBS
Premium
The Fly
Crinetics downgraded to Neutral from Buy at UBS
19d ago
Nuvectis’ NXP100 Just Achieved the First Marketing Approval Ever for a Once-Daily Oral Factor B Inhibitor
Premium
TipRanks Newswire
Nuvectis’ NXP100 Just Achieved the First Marketing Approval Ever for a Once-Daily Oral Factor B Inhibitor
23d ago
The Billion-Dollar Pill: With NXP100, Nuvectis Pharma Just Staked Its Claim in the New Biotech Gold Rush
PremiumTipRanks NewswireThe Billion-Dollar Pill: With NXP100, Nuvectis Pharma Just Staked Its Claim in the New Biotech Gold Rush
1M ago
Crinetics downgraded to Hold from Buy at Stifel
Premium
The Fly
Crinetics downgraded to Hold from Buy at Stifel
1M ago
Crinetics downgraded to In Line from Outperform at Evercore ISI
Premium
The Fly
Crinetics downgraded to In Line from Outperform at Evercore ISI
1M ago
Crinetics rises 98.8%
PremiumThe FlyCrinetics rises 98.8%
1M ago
Crinetics downgraded to Hold from Buy at Jefferies
Premium
The Fly
Crinetics downgraded to Hold from Buy at Jefferies
1M ago
Wedbush sees BioCryst, Ascendis as potential next targets after Crinetics deal
Premium
The Fly
Wedbush sees BioCryst, Ascendis as potential next targets after Crinetics deal
1M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100